Delcath stock.

Delcath Systems, Inc. Common Stock (DCTH) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets.finance.yahoo.com - September 5 at 5:40 PM. Delcath Systems, Inc. Announces Additional $35 Million in Funding Tied to the FDA Approval of HEPZATO KIT™. finance.yahoo.com - September 1 at 3:21 PM. Delcath Systems (DCTH) Price Target Increased by 10.98% to 18.56.Delcath Systems, Inc. Common Stock (DCTH) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets.united states. securities and exchange commission. washington, d.c. 20549 . form 10-q. x. quarterly report pursuant to section 13 or 15(d) of the securities exchange act of 1934According to the issued ratings of 4 analysts in the last year, the consensus rating for Delcath Systems stock is Buy based on the current 4 buy ratings for DCTH. The average twelve-month price prediction for Delcath Systems is $18.00 with a high price target of $21.00 and a low price target of $13.00. Learn more on DCTH's analyst rating …

Nov 29, 2023 · According to 4 analysts, the average rating for DCTH stock is "Strong Buy." The 12-month stock price forecast is $18.0, which is an increase of 542.86% from the latest price. Mr Michel DCTH stock SEC Form 4 insiders trading. Mr has made over 25 trades of the Delcath Systems stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 19,646 units of DCTH stock worth $95,087 on 29 March 2023.. The largest trade he's ever made was exercising 112,481 units of Delcath …

Exercise: Stock options may be exercised at any time, once vested, and have true value when the exercise price is more than the grant price of the award. More information on how to exercise stock options are described in greater detail in Delcath’s Amended 2009 Stock Incentive Plan and applicable Awards Agreements. •

What this means: Delcath Systems Inc (DCTH) gets an Overall Rank of 56, which is an above average rank under InvestorsObserver's stock ranking system. Our system considers the available information about the company and then compares it to all the other stocks we have data on to get a percentile-ranked value.PR Newswire (US) NEW YORK, Oct. 10, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the ...united states. securities and exchange commission. washington, d.c. 20549 . form 10-q. x. quarterly report pursuant to section 13 or 15(d) of the securities exchange act of 1934Delcath is in the process of completing its customary quarter-end close and review procedures, including certain valuation work associated with the issuance of warrants and preferred stock in Delcath's previously announced private placement that closed on March 29, 2023, as of and for the quarter ended March 31, 2023, and the final results for ...

Get the latest Delcath Systems Inc (DCTH) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment …

united states. securities and exchange commission. washington, d.c. 20549 . form 10-q. x. quarterly report pursuant to section 13 or 15(d) of the securities exchange act of 1934

March 27, 2023 at 3:15 PM · 2 min read. Delcath Systems Inc (NASDAQ: DCTH) shares are rising over 23% as FDA accepted its new drug application resubmission for HEPZATO Kit (melphalan ...Nov 6, 2023 · On Friday, Delcath Systems Inc [NASDAQ:DCTH] saw its stock fall -2.50% to $3.12. On the same session, the stock had its day’s lowest price of $3.05, but rose to a high of $3.32. Over the last five days, the stock has lost -4.88%. Delcath Systems Inc shares have fallen nearly -13.33% since the year began. Get the latest Delcath Systems Inc (DCTH) stock quote, charts, news, and other financial information to help you make more informed trading and investment decisions. See the company's financial performance, balance sheet, cash flow, and market outlook for the second quarter of 2023.DELCATH SYSTEMS, INC. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant) ... 2006, the day before Laddcap commenced its consent solicitation, the market value per share of common stock has increased by approximately 469%. Delcath's Board of Directors and management …Dec 5, 2022 · Data Provided by Thomson Reuters. Delcath Systems, Inc. (NASDAQ-DCTH) is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. See all of Delcaths investors and understand how they are helping revolutionize how cancer is treated.

If you’re just getting started, tracking investments might seem like a mystery. Thankfully, modern tools and technology make it easier than ever to figure out how to manage your stock portfolio and to track it. This quick guide gives you ti...eRecent News. [2022-12-16] Delcath Systems Announces Inducement of Grant Under NASDAQ Listing Rule 5635 (C) (4) [2022-12-13] Delcath Systems Closes …In other news, COO John Purpura bought 14,505 shares of Delcath Systems stock in a transaction dated Friday, October 13th. The stock was bought at an average price of $3.44 per share, for a total transaction of $49,897.20. Following the purchase, the chief operating officer now owns 41,526 shares of the company’s stock, valued at $142,849.44.Fintel reports that on August 15, 2023, HC Wainwright & Co. maintained coverage of Delcath Systems (NASDAQ:DCTH) with a Buy recommendation. Analyst Price Forecast Suggests 436.15% Upside. As of August 2, 2023, the average one-year price target for Delcath Systems is 16.73. The forecasts range from a low of 10.10 to a high of $23.10.Aug 12, 2023 · Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. With the latest financial year loss of ... Delcath Systems, Inc. (NASDAQ:DCTH – Free Report) – Stock analysts at HC Wainwright lowered their FY2023 earnings per share estimates for shares of Delcath Systems in a report issued on Tuesday, November 14th.HC Wainwright analyst S. Ramakanth now expects that the company will earn ($3.17) per share for the year, down …Get the latest Delcath Systems, Inc. (DCTH) stock quote, history, news and other vital information to help you with your stock trading and investing. See the current price, performance outlook, earnings date, dividend yield, fair value and more.

DCTH : 2.70 (+10.20%) Delcath Systems to Participate in the Lytham Partners Fall 2023 Investor Conference PR Newswire - Tue Oct 10, 7:30AM CDT. /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the...Fintel reports that on August 15, 2023, HC Wainwright & Co. maintained coverage of Delcath Systems (NASDAQ:DCTH) with a Buy recommendation. Analyst Price Forecast Suggests 436.15% Upside. As of August 2, 2023, the average one-year price target for Delcath Systems is 16.73. The forecasts range from a low of 10.10 to a high of $23.10.

Stock Performance. Shares of Delcath Systems were trading at $2.99 as of November 09. Over the last 52-week period, shares are up 6.16%. Given that these returns are generally positive, long-term ...Dec 8, 2022 · Delcath will issue and sell 1,448,889 shares of its common stock (the "Common Stock") at a price per share of $2.90, or, in lieu of shares of Common Stock, 692,042 pre-funded warrants to purchase ... dcth-10q_20150930.htm - SEC.gov ... united statesSep 1, 2023 · Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today that it raised approximately $35 ... Aug 12, 2023 · Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. With the latest financial year loss of ... Aug. 14, 2023 at 5:32 p.m. ET on Benzinga.com. DCTH | Complete Delcath Systems Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full …Beginning with trading on December 24, 2019, shares of Delcath common stock will be designated by the symbol DCTHD for 20 trading days, and thereafter will revert to the symbol DCTH. The new CUSIP ...0001193125-15-285097.txt : 20150810 0001193125-15-285097.hdr.sgml : 20150810 0001193125-15-285097.hdr.sgml : 20150810

PR Newswire (US) NEW YORK, Oct. 10, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the ...

DCTH. --Delcath Systems, Inc., an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported business highlights and financial results ...

In other news, COO John Purpura bought 14,505 shares of Delcath Systems stock in a transaction dated Friday, October 13th. The stock was bought at an average price of $3.44 per share, for a total transaction of $49,897.20. Following the purchase, the chief operating officer now owns 41,526 shares of the company’s stock, valued at $142,849.44.Summary. Delcath Systems received FDA approval for its HEPZATO Kit device as a treatment for liver-dominant eye cancer, resulting in the stock price surging over $7.00. Concerns arise over the ...Mar 27, 2023 · March 27, 2023 at 3:15 PM · 2 min read. Delcath Systems Inc (NASDAQ: DCTH) shares are rising over 23% as FDA accepted its new drug application resubmission for HEPZATO Kit (melphalan ... Nov 15, 2023 · NEW YORK, Nov. 15, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company's Compensation Committee, as a material inducement to the employment of five individuals. Dec 8, 2022 · Delcath will issue and sell 1,448,889 shares of its common stock (the "Common Stock") at a price per share of $2.90, or, in lieu of shares of Common Stock, 692,042 pre-funded warrants to purchase ... Delcath Systems (). The second penny stock we’re looking at here is Delcath Systems, a biotech firm focused on interventional oncology. The company specializes in the development of minimally ...Delcath Systems story: What to Know About Buying Penny Stocks on June 7th StreetInsidercom and other headlines for Delcath SystemsStock analysis for Delcath Systems Inc (DCTH:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Nov 22, 2023 · 15.2%. 10% least volatile stocks in US Market. 2.9%. Stable Share Price: DCTH is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 11% a week. Volatility Over Time: DCTH's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks. Aug 15, 2023 · Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced that today the US Food and Drug ... Aug 15, 2023 · Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced that today the US Food and Drug ...

Get the latest Delcath Systems, Inc. (DCTH) stock news and headlines to help you in your trading and investing decisions.View Our Latest Stock Analysis on DCTH. Delcath Systems Price Performance. NASDAQ DCTH opened at $2.45 on Thursday. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.30 and a quick ratio of 1.53. The stock’s fifty day moving average price is $3.62 and its 200 day moving average price is $4.93.Please contact Delcath’s transfer agent, American Stock Transfer and Trust Company, LLC 6201 15th Ave. Brooklyn, NY 11219 1-800-937-5449 www.amstock.com.Insider Buying: Delcath Systems, Inc. (NASDAQ:DCTH) COO Purchases $49,897.20 in Stock Ticker Report • about 1 month ago Delcath Systems, Inc. (NASDAQ:DCTH Get Free Report) COO John Purpura acquired 14,505 shares of the stock in a transaction dated Friday, October 13th. Instagram:https://instagram. what is the cheapest way to buy goldnyse mdudraftkings stocksstock ranks Dec 1, 2023 · Earnings for Delcath Systems are expected to grow in the coming year, from ($2.43) to ($1.45) per share. Delcath Systems has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, March 25th, 2024 based off prior year's report dates. Read More. real world portal appconocophillipsstock prer14a 1 a42519.htm delcath systems, inc. united states. securities and exchange commission. schedule 14a (rule 14a-101) information required in proxy statement. schedule 14a information. proxy statement pursuant to section 14(a) of the securities exchange act of 1934 (amendment no. __) r.Source: Kantar Media. View the latest Delcath Systems Inc. (DCTH) stock price, news, historical charts, analyst ratings and financial information from WSJ. nasdaq icln Nov 22, 2023 · Delcath Systems to raise $5M in stock and warrants offering SA News Mon, Jul. 18, 2022 Delcath Systems GAAP EPS of -$1.00 misses by $0.12, revenue of $0.38M beats by $0.07M dcth-10q_20150930.htm - SEC.gov ... united states